About: Marc Ychou

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Marc Ychou Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) дослідник (uk) эрдэмтэн (mn) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) onderzoeker (nl)
rdfs:label	Marc Ychou (en) Marc Ychou (es) Marc Ychou (nl) Marc Ychou (ast)
skos:prefLabel	Marc Ychou (en) Marc Ychou (es) Marc Ychou (nl) Marc Ychou (ast)
name	Marc Ychou (en) Marc Ychou (es) Marc Ychou (nl) Marc Ychou (ast)
given name	wds:Q57036797-726BC611-2258-4BE9-B77E-CA5E40EC4D6B
given name	Marc
instance of	wds:Q57036797-FEDACD25-4C10-4393-A720-2B509DEEA969
instance of	Homo sapiens
award received	wds:Q57036797-B2E8C9D6-1C59-499F-A61F-1DE112291BA1
award received	Knight of the National Order of Merit
doctoral student	wds:Q57036797-AEE2A217-56AE-48AA-B18A-D11B6F72CCE7
doctoral student	Thibault Mazard
occupation	wds:Q57036797-13C90335-A225-4B8F-955B-4D35B51F71C7
sex or gender	wds:Q57036797-EE0F8241-A902-46AC-9473-A6698C856C8B
VIAF ID	wds:Q57036797-57A30696-76B7-46DA-A1A2-C8F35AF6A177
IdRef ID	wds:Q57036797-FD608D5B-9053-4625-8734-7C3AD92E549F
date of birth	wds:Q57036797-8F4A49E2-400E-4274-B0E7-82B5C5399CF7
PLWABN ID	wds:Q57036797-42041468-6C61-4837-AECB-7CE9D803117A
VIAF ID	http://viaf.org/viaf/315223536
IdRef ID	http://www.idref.fr/060378360/id
occupation	researcher
sex or gender	male
VIAF ID	315223536
IdRef ID	060378360
date of birth	1959-01-01 00:00:00Z (xsd:dateTime)
PLWABN ID	9810658806605606
ORCID iD	wds:Q57036797-25ED693F-0221-4BE5-8D48-25E0037A9538
ORCID iD	https://orcid.org/0000-0001-7378-9469
ORCID iD	0000-0001-7378-9469
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57036797
is author of	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Docetaxel and Radiotherapy and Pancreatic Cancer Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus be Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers Detection of lymph node metastases in lung cancer: comparison of 131I-anti-CEA-anti-CA 19-9 immunoscintigraphy versus computed tomography Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software